Price$6.06-1.75 (-22.41%)
12:00 PM07:45 PM
News · 26 weeks73-46%
2025-12-282026-06-21
Mix4590d
- SEC Filings18(40%)
- Insider15(33%)
- Other9(20%)
- Earnings2(4%)
- Offering1(2%)
Latest news
25 items- PRIceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast CancerPublished in the International Journal of Surgery, globally ranked in the top three among surgery journals, the article highlights strong clinical outcomes with ProSense® cryoablation and describes thermal ablation as a "beacon of hope for patients IceCure preparing for the 2026 Japanese Breast Cancer Society meeting and planned regulatory submission for breast cancer in Japan by Terumo Corporation one of the world's top 20 medical device companiesCAESAREA, Israel, June 23, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tu
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional InvestorCAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with a single healthcare focused institutional investor, for the purchase and sale of 1,833,334 ordinary shares (or ordinary share equivalents in lieu thereof), Series D Warrants to purchase up to 1,833,334 ordinary shares (the "Series D Warrants") and Series E Warrants to purchase up to 1,833,334 ordinary shares (the "Series E Warrants," and together with the Seri
- PRBiotech's New Frontier: Companies Breaking Through Medicine's Toughest BarriersDENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones NeOnc (NASDAQ:NTHI) is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, the company's ora
- PRIceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA ClearanceIncrease driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences compared to last yearProSense® breast cancer cryoablation procedures have been performed in major cities across the U.S.CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), today reported a 70% increase in its U.S. active commercial install base of ProSense® for breast cancer cryoablation following U.S. Food and Drug Administration (FDA) marketing authorization in October 2025, reflecting accelerating commercial adoptio
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq ComplianceProactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets StrategyCAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (the "Company" or "IceCure" or "IceCure Medical") (NASDAQ:ICCM), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it intends to effect a one-for-thirty reverse split (the "Reverse Share Split") of the Company's ordinary shares, no par value per share, (the "Ordinary Shares"), as part of its proactive efforts to regain compliance with the Nasdaq $1.00 minimum bid price requirement and support its broader capital markets strategy
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- INSIDERSEC Form 4 filed by VP, R&D & Engineering Muchnik Naum4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERNew insider Peleg Meir claimed ownership of 400,000 units of Ordinary shares (SEC Form 3)3 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Tsimerman Ronen4 - IceCure Medical Ltd. (0001584371) (Issuer)
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid RequirementNo Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary SharesCAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received a notification letter from Nasdaq Stock Market LLC ("Nasdaq") that the Company has been granted an additional 180-day compliance period, or until November 9, 2026 to regain compliance with Nasdaq's minimum bid price rule. Nasdaq's determination is based on the Company meeting the continued listing requirement for market
- SECSEC Form 424B5 filed by IceCure Medical Ltd.424B5 - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North AmericaPent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearanceAccelerating adoption of ProSense® driven by several growth catalysts, including FDA clearance, expanding reimbursement framework, media coverage, growing body of clinical data and recommendation of cryoablation for breast cancer in leading clinical guidelinesConference call to be held today at 11:00 am Eastern TimeCAESAREA, Israel, May 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology t
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. MarketAs the only FDA cleared minimally invasive treatment option for low-risk breast cancer, ProSense® is aligned with the trend toward de-escalation of breast cancer treatment—a key theme at this year's meeting American Society of Breast Surgeons (ASBrS) recently recommend cryoablation for low-risk breast cancer in its updated Resource GuideIceCure sponsored a cryoablation symposium led by Key Opinion Leader breast physicians from leading medical institutions including Cleveland Clinic, University of Michigan, West Cancer Center, and the Warren Alpert Medical School of Brown University who shared their thoughts about and their experience using ProSense®Company expects to report U.S. revenue of
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum acceleratesCryoablation cost analysis study from Massachusetts General Hospital featuring ProSense® demonstrated 50% reduction in cost vs. lumpectomy won SBI 2026 Abstract AwardCAESAREA, Israel, April 21, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it expects to report U.S. revenue of ProSense® systems and cryoprobes increased more than 30% in
- SECSEC Form EFFECT filed by IceCure Medical Ltd.EFFECT - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form F-1 filed by IceCure Medical Ltd.F-1 - IceCure Medical Ltd. (0001584371) (Filer)
ICCM FAQ
6 questionsWhat does IceCure Medical Ltd. do?
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.Where does ICCM stock trade?
IceCure Medical Ltd. (ICCM) is listed on NASDAQ.What sector and industry is ICCM in?
IceCure Medical Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about ICCM?
IceCure Medical Ltd. has had 2 recent analyst actions on file. The most recent action was from Brookline Capital: Buy with a $565.00 price target on 2022-02-02. Recent price targets range from $565.00 to $1450.00.What companies are similar to ICCM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare ICCM side-by-side with any of them on Quantisnow.How can I track ICCM on Quantisnow?
Quantisnow aggregates IceCure Medical Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ICCM to receive live email and push alerts on every new disclosure.